A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...

It can happen even after a mild case and at any age, although rates have declined since the pandemic’s early years. Studies show vaccination can lower the risk. It also is not clear what causes long ...

The Centers for Disease Control has authorized expansion of COVID-19 booster doses for all adults.  Berit Spors, director of McLeod County Health and Human Services, told the McLeod County Board ...

I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of ...

Peter Hotez has made every effort to stay up to date with Covid-19 vaccines, starting with the initial two doses and continuing through each booster iteration. “I've gotten every one possible,” he ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Read Also: Why Novavax Stock Is Volatile This Week The news also intensified concerns about diminishing COVID-19 vaccine revenues and broader industry challenges as pandemic-driven demand ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...